Until strong findings emerged from the phase III PROfound study of PARP inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer, targeted therapy had an uncertain foothold in this tumor type.
Kelvin Alexander Moses, MD, PhD, discusses relevant data and treatment decisions in metastatic hormone-sensitive prostate cancer, as well as the role of cytoreductive nephrectomy in RCC.
Select DNA variants leading to methylation dysregulation within the germline DNA of men with localized prostate cancer were found to be predictive of disease biology, suggesting the prognostic capacity of inherited elements of a patient’s genome, according to data published in Nature Medicine.
David F. Penson, MD, MPH, MMHC, discusses the current armamentarium and ongoing research in prostate cancer.
Daniel A. Barocas, MD, MPH, FACS, discusses the CEASAR study in prostate cancer, as well as therapeutic updates in renal cell carcinoma.
China’s National Medical Products Administration has granted approval to enzalutamide for the treatment of patients with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic following progression on androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.
Sam S. Chang, MD, discusses the utility of genetic testing in prostate cancer and pivotal research efforts.
Treatment with relugolix achieved a high rate of sustained testosterone suppression to castrate levels in patients with androgen-sensitive advanced prostate cancer, meeting the primary endpoint of the phase III HERO trial.
Although the oncology community has made many advancements in understanding the role of germline mutations in prostate cancer, a pressing need exists for clarity in determining which genes should be included in testing panels and what steps should be taken to counsel patients at risk and their families.
Alan H. Bryce, MD, discusses encouraging updates and emerging strategies in metastatic prostate cancer treatment.